These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 17113426

  • 1. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 2. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 18; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 3. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 4. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP.
    Gastroenterology; 2008 Nov 10; 135(5):1517-25. PubMed ID: 18823986
    [Abstract] [Full Text] [Related]

  • 5. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 10; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 6. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI.
    Ter Arkh; 2010 Dec 10; 82(8):57-62. PubMed ID: 20873248
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.
    Ann Rheum Dis; 2008 Mar 10; 67(3):315-22. PubMed ID: 17965424
    [Abstract] [Full Text] [Related]

  • 8. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 10; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Dec 10; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 10. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr 10; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 11. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K.
    MMW Fortschr Med; 2006 Nov 30; 148(48):12. PubMed ID: 17615761
    [No Abstract] [Full Text] [Related]

  • 12. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 30; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 13. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
    Curr Med Res Opin; 2004 Dec 30; 20(12):1899-908. PubMed ID: 15701208
    [Abstract] [Full Text] [Related]

  • 14. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D.
    MMW Fortschr Med; 2006 Nov 30; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS.
    Curr Pharm Des; 2007 Nov 30; 13(22):2228-36. PubMed ID: 17691996
    [Abstract] [Full Text] [Related]

  • 16. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP, EDGE Study Group.
    J Rheumatol; 2007 Feb 30; 34(2):408-20. PubMed ID: 17304660
    [Abstract] [Full Text] [Related]

  • 17. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.
    Lancet; 2010 Jul 17; 376(9736):173-9. PubMed ID: 20638563
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP.
    Cardiovasc Ther; 2012 Dec 17; 30(6):342-50. PubMed ID: 21884017
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
    Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP.
    J Hypertens; 2009 Apr 17; 27(4):886-93. PubMed ID: 19516186
    [Abstract] [Full Text] [Related]

  • 20. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF, Siddiqui MA.
    Drugs; 2009 Jul 30; 69(11):1513-32. PubMed ID: 19634927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.